Global Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Comprehensive Study by Type (Duchenne/Becker (DMD/BMD), Myotonic (DM), Limb-Girdle (LGMD), Facioscapulohumeral (FSHD), Congenital (CMD), Oculopharyngeal (OPMD), Emery-Dreifuss (EDMD)), Application (Male, Female), Therapeutic Approach (Molecular-based Therapies (Mutation Suppression, Exon Skipping), Steroid Therapy (Corticosteroids), Nonsteroidal Anti-inflammatory Drugs (NSAIDs), Other Therapeutic Approaches and Treatment Types), End User (Hospitals/Clinics, Ambulatory Centers, Other) Players and Region - Global Market Outlook to 2029

Duchenne Muscular Dystrophy Market by XX Submarkets | Forecast Years 2024-2029  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Duchenne muscular dystrophy is a medical condition that develops due to a shortage of protein called “dystrophin”. It causes deterioration and breaks down muscles, which results in walking difficulty and limited general mobility. Duchenne muscular dystrophy is considered as one of the most progressive childhood neuromuscular disorders. Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness. It is a rare muscle disease, which majorly affects males. There are novel drugs and therapies, disease-modifying, and mutation-specific therapies that are some of the emerging major breakthroughs in the DMD treatment market. it affects boys mostly, but few cases of girls have been registered too.

AttributesDetails
Study Period2019-2029
Base Year2023
High Growth MarketAsia Pacific
UnitValue (USD Million)
Key Companies ProfiledBioMarin (United States), Bristol-Myers Squibb Company (United States), Fibrogen Inc. (United States), Eli Lilly and Company (United States), Nobelpharma Co. Ltd (Japan), NS Pharma Inc. (United States), Pfizer Inc. (United States) and PTC Therapeutics (United States)


This growth is primarily driven by High Demand for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Rising Prevalence of Chronic Diseases.

Globally, a noticeable market trend is evident Increasing Awareness Campaigns for DMD The Diseases & Therapeutic Areas sector in the North America region has been increasing at a sustainable rate, and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as BioMarin (United States), Bristol-Myers Squibb Company (United States), Fibrogen Inc. (United States), Eli Lilly and Company (United States), Nobelpharma Co. Ltd (Japan), NS Pharma Inc. (United States), Pfizer Inc. (United States) and PTC Therapeutics (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.

Key Developments in the Market:
In July , 2023 NS Pharma, Inc. announced today the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to NS-089/NCNP-02, an investigational candidate for patients with Duchenne muscular dystrophy amenable to exon 44 skipping therapy.
In April , 2023, REGENXBIO Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne muscular dystrophy (Duchenne).

Influencing Trend:
Increasing Awareness Campaigns for DMD and Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)

Market Growth Drivers:
High Demand for Nonsteroidal Anti-inflammatory Drugs (NSAIDs) and Rising Prevalence of Chronic Diseases

Challenges:
Stringent Government Regulations and Increasing Concern Related High Product Cost

Restraints:
Lack of Standardization to Measure Clinical Efficacy Across All Stages of DMD

Opportunities:
Upsurging Investments in Biopharmaceutical R&D to Release Novel Disease Therapies and Increasing Awareness among People and With the Government’s Urgency for the Treatment of the Disease

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Duchenne Muscular Dystrophy Market
- Analysis about New Entrants in Duchenne Muscular Dystrophy Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Duchenne Muscular Dystrophy Study Sheds Light on
— The Duchenne Muscular Dystrophy Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Duchenne Muscular Dystrophy industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Duchenne Muscular Dystrophy industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Duchenne/Becker (DMD/BMD)
  • Myotonic (DM)
  • Limb-Girdle (LGMD)
  • Facioscapulohumeral (FSHD)
  • Congenital (CMD)
  • Oculopharyngeal (OPMD)
  • Emery-Dreifuss (EDMD)
By Application
  • Male
  • Female
By Therapeutic Approach
  • Molecular-based Therapies [Mutation Suppression, Exon Skipping]
  • Steroid Therapy [Corticosteroids]
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
  • Other Therapeutic Approaches and Treatment Types

By End User
  • Hospitals/Clinics
  • Ambulatory Centers
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Demand for Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
      • 3.2.2. Rising Prevalence of Chronic Diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Regulations
      • 3.3.2. Increasing Concern Related High Product Cost
    • 3.4. Market Trends
      • 3.4.1. Increasing Awareness Campaigns for DMD
      • 3.4.2. Rising Disease Burden of Duchenne Muscular Dystrophy (DMD)
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Duchenne Muscular Dystrophy, by Type, Application, Therapeutic Approach, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Duchenne Muscular Dystrophy (Value)
      • 5.2.1. Global Duchenne Muscular Dystrophy by: Type (Value)
        • 5.2.1.1. Duchenne/Becker (DMD/BMD)
        • 5.2.1.2. Myotonic (DM)
        • 5.2.1.3. Limb-Girdle (LGMD)
        • 5.2.1.4. Facioscapulohumeral (FSHD)
        • 5.2.1.5. Congenital (CMD)
        • 5.2.1.6. Oculopharyngeal (OPMD)
        • 5.2.1.7. Emery-Dreifuss (EDMD)
      • 5.2.2. Global Duchenne Muscular Dystrophy by: Application (Value)
        • 5.2.2.1. Male
        • 5.2.2.2. Female
      • 5.2.3. Global Duchenne Muscular Dystrophy by: Therapeutic Approach (Value)
        • 5.2.3.1. Molecular-based Therapies [Mutation Suppression, Exon Skipping]
        • 5.2.3.2. Steroid Therapy [Corticosteroids]
        • 5.2.3.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 5.2.3.4. Other Therapeutic Approaches and Treatment Types
      • 5.2.4. Global Duchenne Muscular Dystrophy by: End User (Value)
        • 5.2.4.1. Hospitals/Clinics
        • 5.2.4.2. Ambulatory Centers
        • 5.2.4.3. Other
      • 5.2.5. Global Duchenne Muscular Dystrophy Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Duchenne Muscular Dystrophy (Price)
      • 5.3.1. Global Duchenne Muscular Dystrophy by: Type (Price)
  • 6. Duchenne Muscular Dystrophy: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioMarin (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Fibrogen Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Nobelpharma Co. Ltd (Japan)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. NS Pharma Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. PTC Therapeutics (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Duchenne Muscular Dystrophy Sale, by Type, Application, Therapeutic Approach, End User and Region (value and price ) (2024-2029)
    • 7.1. Introduction
    • 7.2. Global Duchenne Muscular Dystrophy (Value)
      • 7.2.1. Global Duchenne Muscular Dystrophy by: Type (Value)
        • 7.2.1.1. Duchenne/Becker (DMD/BMD)
        • 7.2.1.2. Myotonic (DM)
        • 7.2.1.3. Limb-Girdle (LGMD)
        • 7.2.1.4. Facioscapulohumeral (FSHD)
        • 7.2.1.5. Congenital (CMD)
        • 7.2.1.6. Oculopharyngeal (OPMD)
        • 7.2.1.7. Emery-Dreifuss (EDMD)
      • 7.2.2. Global Duchenne Muscular Dystrophy by: Application (Value)
        • 7.2.2.1. Male
        • 7.2.2.2. Female
      • 7.2.3. Global Duchenne Muscular Dystrophy by: Therapeutic Approach (Value)
        • 7.2.3.1. Molecular-based Therapies [Mutation Suppression, Exon Skipping]
        • 7.2.3.2. Steroid Therapy [Corticosteroids]
        • 7.2.3.3. Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
        • 7.2.3.4. Other Therapeutic Approaches and Treatment Types
      • 7.2.4. Global Duchenne Muscular Dystrophy by: End User (Value)
        • 7.2.4.1. Hospitals/Clinics
        • 7.2.4.2. Ambulatory Centers
        • 7.2.4.3. Other
      • 7.2.5. Global Duchenne Muscular Dystrophy Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Duchenne Muscular Dystrophy (Price)
      • 7.3.1. Global Duchenne Muscular Dystrophy by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Duchenne Muscular Dystrophy: by Type(USD Million)
  • Table 2. Duchenne Muscular Dystrophy Duchenne/Becker (DMD/BMD) , by Region USD Million (2018-2023)
  • Table 3. Duchenne Muscular Dystrophy Myotonic (DM) , by Region USD Million (2018-2023)
  • Table 4. Duchenne Muscular Dystrophy Limb-Girdle (LGMD) , by Region USD Million (2018-2023)
  • Table 5. Duchenne Muscular Dystrophy Facioscapulohumeral (FSHD) , by Region USD Million (2018-2023)
  • Table 6. Duchenne Muscular Dystrophy Congenital (CMD) , by Region USD Million (2018-2023)
  • Table 7. Duchenne Muscular Dystrophy Oculopharyngeal (OPMD) , by Region USD Million (2018-2023)
  • Table 8. Duchenne Muscular Dystrophy Emery-Dreifuss (EDMD) , by Region USD Million (2018-2023)
  • Table 9. Duchenne Muscular Dystrophy: by Application(USD Million)
  • Table 10. Duchenne Muscular Dystrophy Male , by Region USD Million (2018-2023)
  • Table 11. Duchenne Muscular Dystrophy Female , by Region USD Million (2018-2023)
  • Table 12. Duchenne Muscular Dystrophy: by Therapeutic Approach(USD Million)
  • Table 13. Duchenne Muscular Dystrophy Molecular-based Therapies [Mutation Suppression, Exon Skipping] , by Region USD Million (2018-2023)
  • Table 14. Duchenne Muscular Dystrophy Steroid Therapy [Corticosteroids] , by Region USD Million (2018-2023)
  • Table 15. Duchenne Muscular Dystrophy Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2018-2023)
  • Table 16. Duchenne Muscular Dystrophy Other Therapeutic Approaches and Treatment Types , by Region USD Million (2018-2023)
  • Table 17. Duchenne Muscular Dystrophy: by End User(USD Million)
  • Table 18. Duchenne Muscular Dystrophy Hospitals/Clinics , by Region USD Million (2018-2023)
  • Table 19. Duchenne Muscular Dystrophy Ambulatory Centers , by Region USD Million (2018-2023)
  • Table 20. Duchenne Muscular Dystrophy Other , by Region USD Million (2018-2023)
  • Table 21. South America Duchenne Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 22. South America Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 23. South America Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 24. South America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 25. South America Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 26. Brazil Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 27. Brazil Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 28. Brazil Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 29. Brazil Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 30. Argentina Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 31. Argentina Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 32. Argentina Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 33. Argentina Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 34. Rest of South America Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 35. Rest of South America Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 36. Rest of South America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 37. Rest of South America Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 38. Asia Pacific Duchenne Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 40. Asia Pacific Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 41. Asia Pacific Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 42. Asia Pacific Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 43. China Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 44. China Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 45. China Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 46. China Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 47. Japan Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 48. Japan Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 49. Japan Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 50. Japan Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 51. India Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 52. India Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 53. India Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 54. India Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 55. South Korea Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 56. South Korea Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 57. South Korea Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 58. South Korea Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 59. Taiwan Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 60. Taiwan Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 61. Taiwan Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 62. Taiwan Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 63. Australia Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 64. Australia Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 65. Australia Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 66. Australia Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 71. Europe Duchenne Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 72. Europe Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 73. Europe Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 74. Europe Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 75. Europe Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 76. Germany Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 77. Germany Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 78. Germany Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 79. Germany Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 80. France Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 81. France Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 82. France Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 83. France Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 84. Italy Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 85. Italy Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 86. Italy Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 87. Italy Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 88. United Kingdom Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 89. United Kingdom Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 90. United Kingdom Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 91. United Kingdom Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 92. Netherlands Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 93. Netherlands Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 94. Netherlands Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 95. Netherlands Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 96. Rest of Europe Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 97. Rest of Europe Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 98. Rest of Europe Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 99. Rest of Europe Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 100. MEA Duchenne Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 101. MEA Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 102. MEA Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 103. MEA Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 104. MEA Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 105. Middle East Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 106. Middle East Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 107. Middle East Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 108. Middle East Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 109. Africa Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 110. Africa Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 111. Africa Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 112. Africa Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 113. North America Duchenne Muscular Dystrophy, by Country USD Million (2018-2023)
  • Table 114. North America Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 115. North America Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 116. North America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 117. North America Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 118. United States Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 119. United States Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 120. United States Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 121. United States Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 122. Canada Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 123. Canada Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 124. Canada Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 125. Canada Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 126. Mexico Duchenne Muscular Dystrophy, by Type USD Million (2018-2023)
  • Table 127. Mexico Duchenne Muscular Dystrophy, by Application USD Million (2018-2023)
  • Table 128. Mexico Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2018-2023)
  • Table 129. Mexico Duchenne Muscular Dystrophy, by End User USD Million (2018-2023)
  • Table 130. Duchenne Muscular Dystrophy: by Type(USD/Units)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Duchenne Muscular Dystrophy: by Type(USD Million)
  • Table 140. Duchenne Muscular Dystrophy Duchenne/Becker (DMD/BMD) , by Region USD Million (2024-2029)
  • Table 141. Duchenne Muscular Dystrophy Myotonic (DM) , by Region USD Million (2024-2029)
  • Table 142. Duchenne Muscular Dystrophy Limb-Girdle (LGMD) , by Region USD Million (2024-2029)
  • Table 143. Duchenne Muscular Dystrophy Facioscapulohumeral (FSHD) , by Region USD Million (2024-2029)
  • Table 144. Duchenne Muscular Dystrophy Congenital (CMD) , by Region USD Million (2024-2029)
  • Table 145. Duchenne Muscular Dystrophy Oculopharyngeal (OPMD) , by Region USD Million (2024-2029)
  • Table 146. Duchenne Muscular Dystrophy Emery-Dreifuss (EDMD) , by Region USD Million (2024-2029)
  • Table 147. Duchenne Muscular Dystrophy: by Application(USD Million)
  • Table 148. Duchenne Muscular Dystrophy Male , by Region USD Million (2024-2029)
  • Table 149. Duchenne Muscular Dystrophy Female , by Region USD Million (2024-2029)
  • Table 150. Duchenne Muscular Dystrophy: by Therapeutic Approach(USD Million)
  • Table 151. Duchenne Muscular Dystrophy Molecular-based Therapies [Mutation Suppression, Exon Skipping] , by Region USD Million (2024-2029)
  • Table 152. Duchenne Muscular Dystrophy Steroid Therapy [Corticosteroids] , by Region USD Million (2024-2029)
  • Table 153. Duchenne Muscular Dystrophy Nonsteroidal Anti-inflammatory Drugs (NSAIDs) , by Region USD Million (2024-2029)
  • Table 154. Duchenne Muscular Dystrophy Other Therapeutic Approaches and Treatment Types , by Region USD Million (2024-2029)
  • Table 155. Duchenne Muscular Dystrophy: by End User(USD Million)
  • Table 156. Duchenne Muscular Dystrophy Hospitals/Clinics , by Region USD Million (2024-2029)
  • Table 157. Duchenne Muscular Dystrophy Ambulatory Centers , by Region USD Million (2024-2029)
  • Table 158. Duchenne Muscular Dystrophy Other , by Region USD Million (2024-2029)
  • Table 159. South America Duchenne Muscular Dystrophy, by Country USD Million (2024-2029)
  • Table 160. South America Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 161. South America Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 162. South America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 163. South America Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 164. Brazil Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 165. Brazil Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 166. Brazil Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 167. Brazil Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 168. Argentina Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 169. Argentina Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 170. Argentina Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 171. Argentina Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 172. Rest of South America Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 173. Rest of South America Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 174. Rest of South America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 175. Rest of South America Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 176. Asia Pacific Duchenne Muscular Dystrophy, by Country USD Million (2024-2029)
  • Table 177. Asia Pacific Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 178. Asia Pacific Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 179. Asia Pacific Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 180. Asia Pacific Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 181. China Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 182. China Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 183. China Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 184. China Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 185. Japan Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 186. Japan Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 187. Japan Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 188. Japan Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 189. India Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 190. India Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 191. India Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 192. India Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 193. South Korea Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 194. South Korea Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 195. South Korea Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 196. South Korea Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 197. Taiwan Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 198. Taiwan Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 199. Taiwan Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 200. Taiwan Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 201. Australia Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 202. Australia Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 203. Australia Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 204. Australia Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 205. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 206. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 207. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 208. Rest of Asia-Pacific Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 209. Europe Duchenne Muscular Dystrophy, by Country USD Million (2024-2029)
  • Table 210. Europe Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 211. Europe Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 212. Europe Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 213. Europe Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 214. Germany Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 215. Germany Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 216. Germany Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 217. Germany Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 218. France Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 219. France Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 220. France Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 221. France Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 222. Italy Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 223. Italy Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 224. Italy Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 225. Italy Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 226. United Kingdom Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 227. United Kingdom Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 228. United Kingdom Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 229. United Kingdom Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 230. Netherlands Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 231. Netherlands Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 232. Netherlands Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 233. Netherlands Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 234. Rest of Europe Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 235. Rest of Europe Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 236. Rest of Europe Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 237. Rest of Europe Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 238. MEA Duchenne Muscular Dystrophy, by Country USD Million (2024-2029)
  • Table 239. MEA Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 240. MEA Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 241. MEA Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 242. MEA Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 243. Middle East Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 244. Middle East Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 245. Middle East Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 246. Middle East Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 247. Africa Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 248. Africa Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 249. Africa Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 250. Africa Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 251. North America Duchenne Muscular Dystrophy, by Country USD Million (2024-2029)
  • Table 252. North America Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 253. North America Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 254. North America Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 255. North America Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 256. United States Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 257. United States Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 258. United States Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 259. United States Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 260. Canada Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 261. Canada Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 262. Canada Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 263. Canada Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 264. Mexico Duchenne Muscular Dystrophy, by Type USD Million (2024-2029)
  • Table 265. Mexico Duchenne Muscular Dystrophy, by Application USD Million (2024-2029)
  • Table 266. Mexico Duchenne Muscular Dystrophy, by Therapeutic Approach USD Million (2024-2029)
  • Table 267. Mexico Duchenne Muscular Dystrophy, by End User USD Million (2024-2029)
  • Table 268. Duchenne Muscular Dystrophy: by Type(USD/Units)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Duchenne Muscular Dystrophy: by Type USD Million (2018-2023)
  • Figure 5. Global Duchenne Muscular Dystrophy: by Application USD Million (2018-2023)
  • Figure 6. Global Duchenne Muscular Dystrophy: by Therapeutic Approach USD Million (2018-2023)
  • Figure 7. Global Duchenne Muscular Dystrophy: by End User USD Million (2018-2023)
  • Figure 8. South America Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 9. Asia Pacific Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 10. Europe Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 11. MEA Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 12. North America Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 13. Global Duchenne Muscular Dystrophy: by Type USD/Units (2018-2023)
  • Figure 14. Global Duchenne Muscular Dystrophy share by Players 2023 (%)
  • Figure 15. Global Duchenne Muscular Dystrophy share by Players (Top 3) 2023(%)
  • Figure 16. Global Duchenne Muscular Dystrophy share by Players (Top 5) 2023(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. BioMarin (United States) Revenue, Net Income and Gross profit
  • Figure 19. BioMarin (United States) Revenue: by Geography 2023
  • Figure 20. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2023
  • Figure 22. Fibrogen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Fibrogen Inc. (United States) Revenue: by Geography 2023
  • Figure 24. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly and Company (United States) Revenue: by Geography 2023
  • Figure 26. Nobelpharma Co. Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 27. Nobelpharma Co. Ltd (Japan) Revenue: by Geography 2023
  • Figure 28. NS Pharma Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. NS Pharma Inc. (United States) Revenue: by Geography 2023
  • Figure 30. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer Inc. (United States) Revenue: by Geography 2023
  • Figure 32. PTC Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 33. PTC Therapeutics (United States) Revenue: by Geography 2023
  • Figure 34. Global Duchenne Muscular Dystrophy: by Type USD Million (2024-2029)
  • Figure 35. Global Duchenne Muscular Dystrophy: by Application USD Million (2024-2029)
  • Figure 36. Global Duchenne Muscular Dystrophy: by Therapeutic Approach USD Million (2024-2029)
  • Figure 37. Global Duchenne Muscular Dystrophy: by End User USD Million (2024-2029)
  • Figure 38. South America Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 39. Asia Pacific Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 40. Europe Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 41. MEA Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 42. North America Duchenne Muscular Dystrophy Share (%), by Country
  • Figure 43. Global Duchenne Muscular Dystrophy: by Type USD/Units (2024-2029)
List of companies from research coverage that are profiled in the study
  • BioMarin (United States)
  • Bristol-Myers Squibb Company (United States)
  • Fibrogen Inc. (United States)
  • Eli Lilly and Company (United States)
  • Nobelpharma Co. Ltd (Japan)
  • NS Pharma Inc. (United States)
  • Pfizer Inc. (United States)
  • PTC Therapeutics (United States)
Additional players considered in the study are as follows:
Santhera Pharmaceuticals (Switzerland) , Sarepta Therapeutics (United States)
Select User Access Type

Key Highlights of Report


Jan 2024 242 Pages 78 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Duchenne Muscular Dystrophy Quantitative research analysis
Global Duchenne Muscular Dystrophy Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Duchenne Muscular Dystrophy market are BioMarin (United States), Bristol-Myers Squibb Company (United States), Fibrogen Inc. (United States), Eli Lilly and Company (United States), Nobelpharma Co. Ltd (Japan), NS Pharma Inc. (United States), Pfizer Inc. (United States) and PTC Therapeutics (United States), to name a few.
North America is dominating the Duchenne Muscular Dystrophy Market.
"Stringent Government Regulations " is seen as one of the major challenges by many Industry Players of Duchenne Muscular Dystrophy Market
The Duchenne Muscular Dystrophy market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Duchenne Muscular Dystrophy market is expected to see a steady growth rate during projected year 2023 to 2029.

Know More About Global Duchenne Muscular Dystrophy Report?

Have a Query? Click Here

Other Related Reports

Diabetic Neuropathy Comprehensive Study by Type (Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), Application (Hospitals, Clinics, Retail Pharmacy, Online Pharmacy...
$ 3750
Donepezil Comprehensive Study by Type (5mg, 10mg, 23mg), Application (Hospitals, Clinics, Drugstore), Distribution Channel (Online, Offline) Players and Region - Global Market Outlook to 2027
$ 3500
Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy, Biological Therapy, Radiation therapy, Targeted therapy), Application (Hospital, Clinic), Mode of Administration (Oral, Injectable), M...
$ 3750
Age Related Macular Degeneration Comprehensive Study by Type (Wet AMD, Dry AMD), Drugs (Lucentis, Eylea, Avastin, Others), Route of Administration (Intravenous, Intravitreal) Players and Region - Glo...
$ 3500
Diabetic Nephropathy Comprehensive Study by Application (Hospitals, Cancer Research Institutes, Diagnostic Labs), Treatment (Medication, Kidney Dialysis, Kidney Transplant), Stages (Microalbuminuria ...
$ 3750
Negative Pressure Wound Therapy Comprehensive Study by Type (Standalone NPWT Devices, Single use Disposable NPWT Devices, Portable NPWT Devices, NPWT Accessories (Canister)), Application (Hospital, C...
$ 3350